TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Geoffrey R. Oxnard(Foundation Medicine (United States)), Myung‐Ju Ahn(Sungkyunkwan University), Kōichi Goto(National Cancer Center Hospital East), Kenneth S. Thress(AstraZeneca (United States)), Karthick Vishwanathan(AstraZeneca (United States)), Leora Horn(Vanderbilt University), Helen Mann(AstraZeneca (United Kingdom)), Dana Ghiorghiu(AstraZeneca (United Kingdom)), Suresh S. Ramalingam(Emory University), Yuichiro Ohe(National Cancer Center), Hideo Saka(Nagoya Medical Center), Seung‐Whan Kim(Ulsan College), Helena A. Yu(Memorial Sloan Kettering Cancer Center), J.C.-H. Yang(National Taiwan University Hospital), Melanie M. Frigault(Vifor Pharma (United States))
Annals of Oncology
March 2, 2020
10.1016/j.annonc.2020.01.013
Cited by 443

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k